Australia's most trusted
source of pharma news
Posted 7 November 2024 AM
Investment in generative artificial intelligence in the pharmaceutical industry will boom over the next few years, giving a competitive advantage to early adopters, according to S&P Global.
In a report, S&P Global Ratings AI in Pharmaceuticals Promises Innovation, Speed and Savings, the analysts noted that all larger pharmas either have proprietary AI platforms used in research, or use third-party solutions integrated into their R&D. They're also partnering with smaller AI-driven pharmas to accelerate drug discovery processes.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.